Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1210/endrev/bnaa011 http://scihub22266oqcxt.onion/10.1210/endrev/bnaa011 32294179!7184382!32294179     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocr+Rev 2020 ; 41 (3): ä Nephropedia Template TP {{tp|p=32294179|t=2020. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications |pdf=|usr=}}{{32294179}} gab.com Text Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications JO: Endocr Rev http://www.kidney.de/pget.php?&tw=1&pmid=32294179 #FOAvip Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection. Twit Text FOAVip Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications ????Endocr Rev http://www.kidney.de/pget.php?&tw=1&pmid=32294179 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32294179 #FOAvip English Wikipedia <ref>{{Cite pmid|32294179}}</ref> Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications #MMPMID32294179 Drucker DJ Endocr Rev 2020[Jun]; 41 (3): ä PMID32294179show ga Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection. |*Betacoronavirus[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Animals[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/metabolism[MESH] |Diabetes Mellitus, Type 1/complications/metabolism[MESH] |Diabetes Mellitus, Type 2/*complications/*drug therapy/metabolism[MESH] |Dipeptidyl Peptidase 4/metabolism[MESH] |Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use[MESH] |Gastrointestinal Tract/metabolism[MESH] |Humans[MESH] |Insulin/therapeutic use[MESH] |Lung/metabolism[MESH] |Obesity/complications/metabolism[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/metabolism[MESH] |Pneumonia, Viral/*complications/metabolism[MESH] |Receptors, Coronavirus[MESH] |Receptors, Virus/metabolism[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therap(epmc).pdf DeepDyve Pubget Overpricing